Aetna modified CPB 0561 for celiac disease laboratory testing, effective September 26, 2025. Here's what changes for billing teams.
Aetna, a CVS Health company, updated its celiac disease laboratory testing coverage policy under CPB 0561 to refine medical necessity criteria across serological, total IgA, genetic, and IgG-specific antibody tests. The update directly affects CPT codes 86364 (tissue transglutaminase), 86258 (deamidated gliadin peptide antibody), 82784 (IgA quantification), 81382 (HLA Class II typing), and 83516/83520 (immunoassays), along with 46 additional codes. If your lab, gastroenterology, or endocrinology billing team runs Aetna claims for celiac testing, read this before September 26, 2025.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Celiac Disease Laboratory Testing |
| Policy Code | CPB 0561 |
| Change Type | Modified |
| Effective Date | September 26, 2025 |
| Impact Level | Medium |
| Specialties Affected | Gastroenterology, endocrinology, clinical laboratory, internal medicine, pediatrics |
| Key Action | Audit charge capture for CPT 86364, 86258, 82784, and 81382 against updated indication-specific criteria before September 26, 2025 |
Aetna Celiac Disease Laboratory Testing Coverage Criteria and Medical Necessity Requirements 2025
The Aetna celiac disease coverage policy draws sharp lines between four categories of tests. Each has its own medical necessity criteria. Getting the indication wrong is how you generate a claim denial.
Serological Testing (TTG, DGP, EMA)
Aetna covers IgA anti-human tissue transglutaminase (TTG) antibodies, IgG and IgA deamidated gliadin peptide (DGP) antibodies, and IgA anti-endomysial antibodies (EMA) — billed under CPT 86364 and 86258 — for four indications. First, as a preliminary diagnostic test for patients with symptoms suggesting celiac disease. Second, to monitor response to a gluten-free diet. Third, to screen first-degree relatives of a confirmed celiac patient. Fourth, to screen patients with type 1 diabetes (ICD-10 E10.10–E10.9) for celiac disease.
That fourth indication is worth flagging. Aetna explicitly names type 1 diabetes as a covered screening indication. If your endocrinology team is ordering celiac panels on T1D patients and using TTG or DGP codes, those claims have a clear medical necessity path — as long as you document the diabetes diagnosis correctly.
Total Serum IgA (CPT 82784)
Aetna covers measurement of total serum IgA, billed under CPT 82784, for celiac disease diagnosis. This is the baseline test that determines whether standard IgA-based serological results are even interpretable. If a patient has selective IgA deficiency, the TTG-IgA test will produce a false negative. Total IgA measurement is what catches that. Bill 82784 as a standalone covered service when the clinical scenario calls for it.
HLA Genetic Testing (CPT 81382)
This is where the criteria get specific — and where most denials will happen if teams aren't paying attention. Aetna covers HLA-DQ2 and HLA-DQ8 genetic testing, billed under CPT 81382, only for five narrow indications:
| # | Covered Indication |
|---|---|
| 1 | Seronegative patients with equivocal small bowel histology (Marsh I–II findings) |
| 2 | Patients already on a gluten-free diet before any serological testing was done |
| 3 | Patients with discrepant celiac-specific serology and histology results |
| 4 | Patients with suspected refractory celiac disease where the original diagnosis is in question |
| 5 | Patients with Down syndrome |
HLA genetic testing is not a first-line diagnostic tool under this policy. Ordering it before serological testing — or without one of these five indications — will get the claim denied. Document the specific clinical reason for the test in the record before you submit.
IgG-TTG and IgG-EMA
Aetna covers IgG-class TTG and EMA testing for patients with symptoms of celiac disease who have a documented low IgA or selective IgA deficiency. This is the logical follow-up when CPT 82784 confirms IgA deficiency and serological IgA tests aren't reliable. Make sure the IgA deficiency is in the chart and coded before submitting the IgG antibody tests.
Prior authorization requirements are not explicitly spelled out in the CPB 0561 policy text, but that doesn't mean your plan isn't enforcing them. Check plan-level prior auth rules for CPT 81382 before you submit genetic testing claims — genetic testing prior authorization requirements vary by Aetna product.
Aetna Celiac Disease Laboratory Testing Exclusions and Non-Covered Indications
CPB 0561 explicitly designates several tests as not medically necessary for celiac disease. These show up in the code table under the exclusions group, and billing them for celiac indications will result in denial.
The excluded tests include fecal fat measurements (CPT 82705–82710), xylose absorption testing (CPT 84620), anti-smooth muscle antibody (CPT 86015), ANCA (CPT 86036–86037), beta-2 glycoprotein antibody (CPT 86146), cardiolipin antibody (CPT 86147), antiphosphatidylserine antibody (CPT 86148), mitochondrial antibody (CPT 86381), serum neurotensin, and several hepatitis-related codes (CPT 86704–86707, 87340, 87341, 87350).
The real issue here is that some of these codes get bundled into broad autoimmune or malabsorption workup panels. If your lab orders them reflexively as part of a celiac panel, Aetna will deny the celiac disease diagnosis as the indication. Pull these codes out of any standing celiac disease order sets and document separate clinical justification if they're ordered alongside celiac testing.
Capillary blood collection (CPT 36416) and HLA low-resolution typing (CPT 81376) also appear in the non-covered group for celiac testing purposes. Low-resolution HLA typing (81376) is specifically excluded — Aetna requires high-resolution HLA typing (81382) when genetic testing is covered. That's a meaningful distinction. If your lab defaults to 81376 for HLA typing, the claim won't be covered under CPB 0561.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Preliminary diagnostic testing — symptoms suggestive of celiac disease | Covered | 86364, 86258, 83516, 83520 | IgA TTG, DGP, EMA serological tests |
| Monitoring response to gluten-free diet | Covered | 86364, 86258 | Requires celiac diagnosis already established |
| Screening first-degree relatives of celiac patients | Covered | 86364, 86258 | Document family history in the record |
| Screening type 1 diabetes patients for celiac disease | Covered | 86364, 86258 | ICD-10 E10.10–E10.9 required |
| Total serum IgA measurement for celiac diagnosis | Covered | 82784 | Needed to interpret IgA-based serology results |
| HLA-DQ2/DQ8 testing — seronegative with equivocal Marsh I–II histology | Covered | 81382 | High-resolution HLA typing only |
| HLA-DQ2/DQ8 testing — patient on gluten-free diet before serology | Covered | 81382 | Document that no prior serological testing was done |
| HLA-DQ2/DQ8 testing — discrepant serology and histology | Covered | 81382 | Both results must be documented |
| HLA-DQ2/DQ8 testing — suspected refractory celiac, diagnosis uncertain | Covered | 81382 | Original diagnosis in question |
| HLA-DQ2/DQ8 testing — Down syndrome | Covered | 81382 | ICD-10 F84.x codes may apply |
| IgG-TTG and IgG-EMA — IgA deficiency | Covered | 86364, 86258 | Must document low IgA or selective IgA deficiency via 82784 |
| Fecal fat testing (CPT 82705–82710) for celiac | Not Covered | 82705, 82706, 82707, 82708, 82709, 82710 | Excluded for celiac disease indication |
| Xylose absorption test (CPT 84620) for celiac | Not Covered | 84620 | Excluded for celiac disease indication |
| Low-resolution HLA typing (CPT 81376) | Not Covered | 81376 | High-resolution (81382) required if HLA testing is covered |
| Hepatitis serology codes (86704–86707, 87340–87350) for celiac | Not Covered | 86704, 86705, 86706, 86707, 87340, 87341, 87350 | Not covered under celiac disease indication |
| Cardiolipin, ANCA, beta-2 glycoprotein, antiphosphatidylserine antibodies | Not Covered | 86146, 86147, 86148, 86036, 86037 | Not covered under celiac disease indication |
Aetna Celiac Disease Laboratory Testing Billing Guidelines and Action Items 2025
These are the actions your billing and lab operations teams need to take before September 26, 2025.
| # | Action Item |
|---|---|
| 1 | Audit your celiac order sets now. Pull every standing order set that includes celiac-related testing. Remove CPT 82705–82710, 84620, 86015, 86036, 86037, 86146, 86147, 86148, 86381, and hepatitis antibody codes from any panel labeled as celiac disease workup. Leaving them in generates automatic denials. |
| 2 | Replace CPT 81376 with 81382 for HLA typing. If your lab defaults to low-resolution HLA typing under 81376, that code is not covered for celiac disease under CPB 0561. High-resolution typing under 81382 is the covered code. Update your charge capture and lab order master files before the effective date. |
| 3 | Document the clinical indication for HLA testing explicitly. For every CPT 81382 claim, the chart must support one of the five specific indications Aetna recognizes. A general "rule out celiac" notation won't hold up on audit. Train ordering providers to document the specific reason — seronegative with Marsh I–II histology, prior gluten-free diet, discrepant results, refractory disease, or Down syndrome. |
| 4 | Build the IgA deficiency flag into your IgG antibody workflow. When a patient's CPT 82784 result shows low or absent IgA, that result needs to be in the chart and coded before IgG-TTG or IgG-EMA claims go out. Build this as a workflow dependency, not an afterthought. Reimbursement for the IgG-class tests depends on it. |
| 5 | Add T1D as a confirmed celiac screening indication in your charge capture. Type 1 diabetes (E10.10–E10.9) is an explicit covered indication for TTG, DGP, and EMA serological testing. If your endocrinology billing team isn't linking celiac panels to diabetes diagnoses on Aetna claims, they're leaving covered claims at risk for denial on the wrong indication. |
| 6 | Check prior authorization requirements at the plan level for CPT 81382. Genetic testing prior authorization requirements under Aetna vary by product line. CPB 0561 establishes medical necessity criteria, but individual Aetna plan documents may still require prior auth for HLA testing. Verify before submitting, especially for commercial and self-funded accounts. |
If you're not sure how this applies to your payer mix or lab billing structure, talk to your compliance officer or billing consultant before September 26, 2025. The genetic testing criteria in particular are narrow enough that a documentation gap creates real financial exposure.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Celiac Disease Laboratory Testing Under CPB 0561
Covered CPT Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 81382 | CPT | HLA Class II typing, high resolution; one locus (e.g., HLA-DRB1, -DRB3) |
| 82784 | CPT | Gammaglobulin; IgA, IgD, IgG, IgM, each |
| 83516 | CPT | Immunoassay for analyte other than infectious agent antibody or antigen, qualitative |
| 83520 | CPT | Immunoassay, analyte, quantitative; not otherwise specified |
| 86255 | CPT | Fluorescent noninfectious agent antibody; screen, each antibody |
| 86362 | CPT | Myelin oligodendrocyte glycoprotein (MOG-IgG1) antibody; cell-based immunofluorescence assay (CBA) |
| 86363 | CPT | Flow cytometry (FACS), each |
| 86828 | CPT | Antibody to HLA, solid phase assays (microspheres or beads, ELISA) |
| 86829 | CPT | Antibody to HLA, solid phase assays |
| 86830 | CPT | Antibody to HLA, solid phase assays |
| 86831 | CPT | Antibody to HLA, solid phase assays |
| 86832 | CPT | Antibody to HLA, solid phase assays |
| 86833 | CPT | Antibody to HLA, solid phase assays |
| 86834 | CPT | Antibody to HLA, solid phase assays |
| 86835 | CPT | Antibody to HLA, solid phase assays |
Not Covered / Excluded Codes for Celiac Disease Indication
| Code | Type | Description | Reason |
|---|---|---|---|
| 36416 | CPT | Collection of capillary blood specimen (e.g., finger, heel, ear stick) | Excluded for celiac disease testing indication |
| 81376 | CPT | HLA Class II typing, low resolution; one locus | Low-resolution typing excluded; use 81382 |
| 82705 | CPT | Fat or lipids, feces; qualitative or quantitative | Excluded for celiac disease indication |
| 82706 | CPT | Fat or lipids, feces; qualitative or quantitative | Excluded for celiac disease indication |
| 82707 | CPT | Fat or lipids, feces; qualitative or quantitative | Excluded for celiac disease indication |
| 82708 | CPT | Fat or lipids, feces; qualitative or quantitative | Excluded for celiac disease indication |
| 82709 | CPT | Fat or lipids, feces; qualitative or quantitative | Excluded for celiac disease indication |
| 82710 | CPT | Fat or lipids, feces; qualitative or quantitative | Excluded for celiac disease indication |
| 84378 | CPT | Sugars (mono-, di-, and oligosaccharides); qualitative or quantitative | Excluded for celiac disease indication |
| 84379 | CPT | Sugars (mono-, di-, and oligosaccharides); qualitative or quantitative | Excluded for celiac disease indication |
| 84620 | CPT | Xylose absorption test, blood and/or urine | Excluded for celiac disease indication |
| 86015 | CPT | Actin (smooth muscle) antibody (ASMA), each | Excluded for celiac disease indication |
| 86036 | CPT | Antineutrophil cytoplasmic antibody (ANCA); screen, each antibody | Excluded for celiac disease indication |
| 86037 | CPT | ANCA titer, each antibody | Excluded for celiac disease indication |
| 86146 | CPT | Beta 2 Glycoprotein I antibody, each | Excluded for celiac disease indication |
| 86147 | CPT | Cardiolipin (phospholipid) antibody, each Ig class | Excluded for celiac disease indication |
| 86148 | CPT | Anti-phosphatidylserine (phospholipid) antibody | Excluded for celiac disease indication |
| 86258 | CPT | Gliadin (deamidated) (DGP) antibody, each immunoglobulin (Ig) class | Excluded under non-covered group context (covered only per serological criteria) |
| 86364 | CPT | Tissue transglutaminase, each immunoglobulin (Ig) class | Listed in non-covered group; covered only per serological criteria |
| 86381 | CPT | Mitochondrial antibody (e.g., M2), each | Excluded for celiac disease indication |
| 86596 | CPT | Voltage-gated calcium channel antibody, each | Excluded for celiac disease indication |
| 86704 | CPT | Hepatitis B core antibody (HBcAb); total | Excluded for celiac disease indication |
| 86705 | CPT | Hepatitis B core antibody; IgM antibody | Excluded for celiac disease indication |
| 86706 | CPT | Hepatitis B surface antibody (HBsAb) | Excluded for celiac disease indication |
| 86707 | CPT | Hepatitis Be antibody (HBeAb) | Excluded for celiac disease indication |
| 87340 | CPT | Infectious agent antigen detection by immunoassay; hepatitis B surface antigen (HBsAg) | Excluded for celiac disease indication |
| 87341 | CPT | Hepatitis B surface antigen (HBsAg) neutralization | Excluded for celiac disease indication |
| 87350 | CPT | Hepatitis Be antigen (HBeAg) | Excluded for celiac disease indication |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| E10.10–E10.9 | Type 1 diabetes mellitus (range) |
| F84.0–F84.9 | Pervasive developmental disorders (including Down syndrome-related codes) |
| I48.0–I48.5 | Atrial fibrillation (range, included in policy scope) |
Get the Full Picture for CPT 86364
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.